請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6474
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳學良(Hsueh-Liang Wu) | |
dc.contributor.author | Song-Guang Guo | en |
dc.contributor.author | 郭松光 | zh_TW |
dc.date.accessioned | 2021-05-17T09:14:04Z | - |
dc.date.available | 2012-12-31 | |
dc.date.available | 2021-05-17T09:14:04Z | - |
dc.date.copyright | 2012-08-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-17 | |
dc.identifier.citation | 1) Al-Laham, A., Amburgey, T. L., & Bates, K. 2008. The Dynamics of Research Alliances: Examining the Effect of Alliance Experience and Partner Characteristics on the Speed of Alliance Entry in the Biotech Industry. British Journal of Management, 19(4): 343-364.
2) Besanko, D. 2010. Economics of strategy. Hoboken, N.J.: J. Wiley & Sons: 136- 144 3) Borghese, R. J., & Borgese, P. 2002. M & A from planning to integration : executing acquisitions and increasing shareholder value. New York: McGraw-Hill: 13-21 4) Bowman, E. H., & Hurry, D. 1993. Strategy through the option lens: An integrated view of resource investments and the incremental-choice process. Academy of management review: 760-782. 5) Carayannopoulos, S., & Auster, E. R. 2010. External knowledge sourcing in biotechnology through acquisition versus alliance: A KBV approach. Research Policy, 39(2): 254-267. 6) Das, T. K., & Teng, B. S. 2000. A Resource-Based Theory of Strategic Alliances. Journal of Management, 26(1): 31-61. 7) Dyer, Jeffrey H., Prashant Kale, and Harbir Singh. 2004. When to ally and when to acquire. Harvard Business Review, 82 (July-August): 108-117. 8) Esteban, E., Lien, F., & Youn, R. 2008. Unbiased insight on biopharma’s innovation crisis. Journal of Business Chemistry, 5(2): 70-77. 9) Gordon, W., & Weber, D. 1984. A Transaction Cost Approach to Make-or-Buy Decisions. Administrative Science Quarterly, 29(3): 373-391. 10) Lin, Z. J., Peng, M. W., Yang, H., & Sun, S. L. 2009. How do networks and learning drive M&As? An institutional comparison between China and the United States. Strategic Management Journal, 30(10): 1113-1132. 11) Liu, H., & Schmid, M. B. 2008. Maturation of the biotechnology industry changes job opportunities for scientists. Journal of Commercial Biotechnology, 15(3): 199-214. 12) Luehrman, T. A. 1998. Strategy as a Portfolio of Options. Harvard Business Review 89-99. 13) Malik, N. N. 2009. Biotech acquisitions by big pharma: why and what is next. Drug Discov Today, 14(17-18): 818-821. 14) Mitsuhashi, H., & Greve, H. 2009. A Matching Theory of Alliance Formation and Organizational Success: Complementarity and Compatibility. The Academy of Management Journal ARCHIVE, 52(5): 975-995. 15) Peng, M. W., Lin, Z., & Yang, H. 2011. Behind Acquisitions of Alliance Partners: Exploratory Learning and Network Embeddedness. The Academy of Management Journal, 54(5): 1069-1080. 16) Porrini, P. 2004. Can a Previous Alliance Between an Acquirer and a Target Affect Acquisition Performance? Journal of Management, 30(4): 545-562. 17) Quelin, C. K. a. B. V. 2010. Real Options and Strategic Investment Decisions: Can They Be of Use to Scholars. Academy of Management prespectives 18) Rankine, D., Howson, Peter. 2006. Acquisition essentials : a step-by-step guide to smarter deals. Harlow: Financial Times Prentice Hall: 2-27. 19) Gunther McGrath, R., & Nerkar, A. (2004). Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms. Strategic Management Journal, 25(1), 1-21. 20) Rothaermel, F. T., & Deeds, D. L. 2004. Exploration and exploitation alliances in biotechnology: a system of new product development. Strategic Management Journal, 25(3): 201-221. 21) Rothaermel, F. T., & Deeds, D. L. 2006. Alliance type, alliance experience and alliance management capability in high-technology ventures. Journal of Business Venturing, 21(4): 429-460. 22) Schilling, M. A. 2009. Understanding the alliance data. Strategic Management Journal, 30(3): 233-260. 23) Vanhaverbeke, W., Duysters, G., & Noorderhaven, N. 2002. External Technology Sourcing through Alliances or Acquisitions: An Analysis of the Application-Specific Integrated Circuits Industry. Organization Science, 13(6): 714-733. 24) Yin, R. K. 2003. Case study research : design and methods. Thousand Oaks, Calif.: Sage Publications. 25) Yin, X., & Shanley, M. 2008. Industry determinants of the' merger versus alliance' decision. The Academy of Management Review ARCHIVE, 33(2): 473-491. 26) Zollo, M., & Reuer, J. J. 2009. Experience Spillovers Across Corporate Development Activities. Organization Science, 21(6): 1195-1212. Online Database 27) Factiva Database 28) Deloitte Recap's 29) United States securities exchange commission: Edgar database 20-F, 10-K http://www.sec.gov/Archives/edgar/data/ 30) United States Securities and Exchange Commission: Form 10-K; Pfizer INC. For the fiscal year ended December 31, 2010 31) United States Securities and Exchange Commission: Form 10-K; Genentech. For the fiscal year ended December, 2004 32) United States Securities and Exchange Commission: Form 10-K; Icagen INC. For the fiscal year ended December , 2010 33) United States Securities and Exchange Commission: Form 10-K; Medarex , 2008 34) United States Securities and Exchange Commission: Form 10-K; Bristol-Myers Squibb 2008 35) United States Securities and Exchange Commission: Form 10-Q; Pfizer INC. For Quarter report, 2011 36) United States Securities and Exchange Commission: From 20-F ; Cambridge Antibody Technology Group, 2004 37) United States Securities and Exchange Commission: From 20-F ; Sanofi-Aventis, 2008 38) United States Securities and Exchange Commission: From 20-F ; AstraZeneca, 2005 Website & Others 39) Sanofi-pasteur website: http://www.sanofipasteur.com 40) Acambis website: http://www.acambis.com 41) CNN Money ranking of global top 500: http://money.cnn.com/magazines/fortune/global500/2010/snapshots/324.html 42) Icagen Website:http://ir.icagen.com/phoenix.zhtml?c=178443&p=irol-newsArticle&ID=1040105&highlight= 43) Icagen Website: http://www.icagen.com/about/corporatestrategy.html 44) News observer (Icagen News): http://www.newsobserver.com/2012/03/22/1949222/icagen-gets-a-new-name-after-being.html#storylink=rss 45) AstraZeneca Website: http://www.astrazeneca.com/Investors/Strategy 46) Wall-Street news biggest merger and acquisition in 2008: http://www.wall-street.ro/articol/English-Version/56433/Biggest-mergers-and-acquisitions-in-2008.html 47) Roche Website: Roche Annual report 2007: http://www.roche.com/index.htm 48) Vaccines growth booster: http://www.bionest.com/publications/VaccinesUpdate_MASTER.pdf 49) Bristol-Myer Squib Website – Sting of pearl strategy: http://www.bms.com/news/features/2011/Pages/BioPharmaandtheStringofPearls.aspx 50) Wall-Street Journal: Big pharma face grim prognosis:http://online.wsj.com/article/SB119689933952615133.html 51) Wall-Street Journal: List of drug that going off patent http://online.wsj.com/public/resources/documents/info-pharma0712-sort.html | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6474 | - |
dc.description.abstract | 在醫藥產業當中,「藥品研發」和「知識資產」是非常重要的能力與資產。藥廠為了快速由外部累積這些資源,通常會選擇透過併購達成。此方法雖然能降低時間成本,但由於企業短期內不易瞭解其合作夥伴,故可能會面臨不確定性以及訊息不對稱的風險。為了降低風險,企業可選擇採取實質選擇權方式,與不同標的(生技公司)進行策略聯盟,而非只投資於一家公司,在合作的過程中逐漸了解對方,等待合適機會再採行併購計劃。本研究以實質選擇權的概念,探討藥廠採行策略聯盟後,在何種因素之下,會由策略聯盟關係走向併購。
本研究選取五組生技醫藥先策略聯盟後併購的個案進行多重個案分析,發現企業由策略聯盟走向併購的過程可劃分成四個階段,並且以實質選擇權觀點來看,在這過程當中有六個因素會促進個案公司決定由策略聯盟關係走向併購:(1)提供多個併購標的選擇、(2)影響並控制標的公司、(3)讓雙方建立互信、(4)確認併購目標是否具備互補能力、(5)可選擇適當時機進行併購,例如當併購標的的研發計劃達到雙放訂定的目標、(6)或當外部環境變化時仍有機會進行併購。 | zh_TW |
dc.description.abstract | Drug discovery pipeline and knowledge asset can be considered as important factors in pharmaceutical industry. In order to gain access to external knowledge and other asset that could support the discovery process, pharmaceutical firms usually adopt acquisition activity since it allows firms to acquire the assets immediately. However firms also have to face with risks from the uncertainty. By considering alliance activities as real options reasoning it could help firms solve the uncertainly and lead to complete acquisition activities. In order to support the use of alliances as options, this research aims to investigate the conditions of “how engaging in alliance (as options) helps facilitate the acquisition of alliance partner subsequently”.
This research applies case study method (Multiple cases) to explain the circumstance, by selecting 5 pair of bio-pharmaceutical firms which have pre-acquisition alliances experiences as study samples. By investigating this issue through real options reasoning lens, this research finds that the situation between sequences of alliances and acquisition could be separated into four steps, in each step contain different conditions that could facilitate firm s’ decision to acquire there alliances partner. The study propose that alliance as option could (1) provides firm opportunities to enjoy variety of choices (2) allows firm to influence & control target, (3) develops mutual understanding between both side, (4) confirms target firm complementary abilities, (5) helps firm to identify the right time to acquire, (6) provides rights to acquire when external factors change. Therefore real options reasoning concept could be consider as a concept that bridge alliance and acquisition together. | en |
dc.description.provenance | Made available in DSpace on 2021-05-17T09:14:04Z (GMT). No. of bitstreams: 1 ntu-101-R99724070-1.pdf: 1150812 bytes, checksum: cf285dd121d6a2eb3e6edf889d39ba22 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | Chapter 1: Introduction 1
1.1 Research Motivation and Scope of study 1 1.2 Research objective and outline 4 Chapter 2: Literature Review 5 2.1 Bio-pharmaceutical industry review 5 2.2 Theoretical Review 8 2.2.1 The challenge: Uncertainty 8 2.2.2 Acquisition: Facing the unknown risk – Uncertainty 9 2.2.3 Alliance: Facing uncertainty with flexibilities 9 2.2.4 Real options reasoning: as a solution to dilute uncertainty problems 10 2.2.5 The sequence: Ally first then acquisition in bio-pharmaceutical industry 11 Chapter 3: Research Method 13 3.1 Case study design & Research Structure 13 3.2 Information collection 16 Chapter 4: Case Background 18 4.1 Pfizer acquires Icagen 18 4.2 Bristol-Myers Squibb acquires Medarex 23 4.3 Sanofi –Aventis acquires Acambis 29 4.4 Cambridge Antibody Technology acquires AstraZeneca 34 4.5 Roche acquires Genentech 39 Chapter 5: Cross cases analysis 46 5.1: Identify the right target 47 5.2: Influence and control 49 5.3: Clarify the logic to acquire 52 5.4: Trigger 58 Chapter 6: Conclusion and further discussion 63 6.1 Conclusion and implementation 63 6.2 Limitation 67 6.3 Further research 68 References 70 | |
dc.language.iso | en | |
dc.title | 實質選擇權觀點於策略聯盟後之併購行為探討: 生技醫藥產業之個案分析 | zh_TW |
dc.title | When did alliance lead to acquisition? Real options view of Pre-acquisition alliances in Bio-Pharmaceutical Industry | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 許煙明,李振宇 | |
dc.subject.keyword | 策略聯盟,併購,併購前策略聯盟,實質選擇權,醫藥產業,生物科技產業, | zh_TW |
dc.subject.keyword | Alliance,Acquisition,Pre-acquisition alliance,Real options reasoning,Pharmaceutical industry,Biotechnology industry, | en |
dc.relation.page | 74 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2012-08-17 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 國際企業學研究所 | zh_TW |
顯示於系所單位: | 國際企業學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf | 1.12 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。